# Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)

> **NCT01071291** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 37 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** Niaspan
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT01071291
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-08
- **Final completion:** 2010-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01071291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01071291, "Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01071291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*